tiprankstipranks
Advertisement
Advertisement

SNY Stock Latest News

Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus
The FlyStifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus
17m ago
SNY
DNTH
Dianthus sinks after Sanofi halts CIDP Phase 3 study
PremiumThe Fly
Dianthus sinks after Sanofi halts CIDP Phase 3 study
26m ago
SNY
DNTH
Sanofi to halt riliprubart Mobilize phase 3 study
PremiumThe Fly
Sanofi to halt riliprubart Mobilize phase 3 study
2h ago
SNY
Sanofi’s Venglustat Wins FDA Priority Review for Type 3 Gaucher Disease
PremiumCompany Announcements
Sanofi’s Venglustat Wins FDA Priority Review for Type 3 Gaucher Disease
2d ago
6K
SNY
Sanofi and Kymera Advance SAR447971 Into First-in-Human Trial, Setting Up New Optionality in Inflammatory Skin Disease
PremiumCompany Announcements
Sanofi and Kymera Advance SAR447971 Into First-in-Human Trial, Setting Up New Optionality in Inflammatory Skin Disease
5d ago
SNY
KYMR
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe FlyActing FDA head vows to block political interference, Endpoint News says
6d ago
AZN
BMY
Snowflake Stock (SNOW) Sinks despite New AI Deals and Offerings
Premium
Market News
Snowflake Stock (SNOW) Sinks despite New AI Deals and Offerings
8d ago
SNY
TRI
Snowflake says Sanofi selects Snowflake Cortex AI for drug development
Premium
The Fly
Snowflake says Sanofi selects Snowflake Cortex AI for drug development
8d ago
SNY
SNOW
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
8d ago
AZN
BMY
Sanofi’s New STRIDE Registry: Tracking Real-World COPD Outcomes for Dupilumab
PremiumCompany Announcements
Sanofi’s New STRIDE Registry: Tracking Real-World COPD Outcomes for Dupilumab
12d ago
SNY
Sanofi announces FDA grants priority review to venglustat new drug application
PremiumThe Fly
Sanofi announces FDA grants priority review to venglustat new drug application
13d ago
SNY
Sanofi’s Efdoralprin Alfa Shows Phase 2 Superiority Over Standard AATD Therapy
PremiumCompany Announcements
Sanofi’s Efdoralprin Alfa Shows Phase 2 Superiority Over Standard AATD Therapy
14d ago
6K
SNY
Sanofi’s Frexalimab Kidney Transplant Trial: A Long-Term Bet With Quiet but Real Upside
PremiumCompany AnnouncementsSanofi’s Frexalimab Kidney Transplant Trial: A Long-Term Bet With Quiet but Real Upside
21d ago
SNY
Trump Trade: Trump announces expansion of TrumpRx.gov
Premium
The Fly
Trump Trade: Trump announces expansion of TrumpRx.gov
22d ago
AZN
BMY
Sanofi reports ElevAATe trial of efdoralprin alfa meets primary endpoint
Premium
The Fly
Sanofi reports ElevAATe trial of efdoralprin alfa meets primary endpoint
23d ago
SNY
PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’
PremiumMarket News
PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’
23d ago
AZN
LLY
Trump to announce ‘dramatic expansion’ of TrumpRx offerings, CNBC says
PremiumThe Fly
Trump to announce ‘dramatic expansion’ of TrumpRx offerings, CNBC says
23d ago
AZN
BMY
Regeneron price target lowered to $707 from $762 at RBC Capital
PremiumThe Fly
Regeneron price target lowered to $707 from $762 at RBC Capital
23d ago
SNY
REGN
Davis to become acting director of CDER after Hoeg exit, Bloomberg says
PremiumThe Fly
Davis to become acting director of CDER after Hoeg exit, Bloomberg says
26d ago
AZN
BMY
Sanofi’s SAR445399 Lung Trial Moves Ahead: What Investors Should Watch
PremiumCompany AnnouncementsSanofi’s SAR445399 Lung Trial Moves Ahead: What Investors Should Watch
27d ago
SNY
Trump Trade: Nvidia CEO joins China trip, Diamantas tapped as acting FDA chief
Premium
The Fly
Trump Trade: Nvidia CEO joins China trip, Diamantas tapped as acting FDA chief
28d ago
AZN
BMY
FDA Commissioner Marty Makary resigns
Premium
The Fly
FDA Commissioner Marty Makary resigns
29d ago
AZN
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >